pubmed-article:11327599 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0026837 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0034328 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C1516170 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
pubmed-article:11327599 | lifeskim:mentions | umls-concept:C0231517 | lld:lifeskim |
pubmed-article:11327599 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:11327599 | pubmed:dateCreated | 2001-4-30 | lld:pubmed |
pubmed-article:11327599 | pubmed:abstractText | In view of its role in tumor promotion and signal transduction, protein kinase C (PKC) has proven to be an exciting target for cancer therapy. With the aid of molecular modeling, we rationally designed and stereoselectively synthesized a new class of rigidified pyrrolidone-based PKC activators. Pyrrolidone 15 was found to exhibit reasonable affinity for PKCdelta, with lower affinity for the other isozymes tested. Pyrrolidone 2 causes the dose-dependent induction of apoptosis in LNCaP prostate cancer cells. This apoptotic effect could be markedly potentiated by the use of LNCaP cells overexpressing the PKCalpha or delta isozymes. | lld:pubmed |
pubmed-article:11327599 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:language | eng | lld:pubmed |
pubmed-article:11327599 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11327599 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11327599 | pubmed:month | Apr | lld:pubmed |
pubmed-article:11327599 | pubmed:issn | 0960-894X | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:FujiiTT | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:WangSS | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:ShawM TMT | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:SavageJJ | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:SenMM | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:KozikowskiA... | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:RothB LBL | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:KazanietzM... | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:ZhaoL YLY | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:Flippen-Ander... | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:RongS BSB | lld:pubmed |
pubmed-article:11327599 | pubmed:author | pubmed-author:RauserLL | lld:pubmed |
pubmed-article:11327599 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11327599 | pubmed:day | 23 | lld:pubmed |
pubmed-article:11327599 | pubmed:volume | 11 | lld:pubmed |
pubmed-article:11327599 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11327599 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11327599 | pubmed:pagination | 955-9 | lld:pubmed |
pubmed-article:11327599 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:meshHeading | pubmed-meshheading:11327599... | lld:pubmed |
pubmed-article:11327599 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11327599 | pubmed:articleTitle | Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. | lld:pubmed |
pubmed-article:11327599 | pubmed:affiliation | Department of Neurology, Georgetotwn University, Medical Center, Washington, DC 20007, USA. | lld:pubmed |
pubmed-article:11327599 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11327599 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:11327599 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11327599 | lld:chembl |